mTNBC
Oncology · 2021–2021
1decision
1medicine
1carried consumer input
1individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| atezolizumab First-line treatment of patients with metastatic triple-negative breast cancer (mTNBC) whose tumours express programmed death ligand 1 (PD-L1) of any intensity… | Mar 2021 | Recommended with restriction | 1 individuals Breast Cancer Network Australia · Medical Oncology Group |
Who spoke
Breast Cancer Network Australia · Medical Oncology Group
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.